JP7398571B2 - 腸内環境改善のためのカスタマイズソリューションを提供する方法及びサーバ - Google Patents
腸内環境改善のためのカスタマイズソリューションを提供する方法及びサーバ Download PDFInfo
- Publication number
- JP7398571B2 JP7398571B2 JP2022544435A JP2022544435A JP7398571B2 JP 7398571 B2 JP7398571 B2 JP 7398571B2 JP 2022544435 A JP2022544435 A JP 2022544435A JP 2022544435 A JP2022544435 A JP 2022544435A JP 7398571 B2 JP7398571 B2 JP 7398571B2
- Authority
- JP
- Japan
- Prior art keywords
- intestinal environment
- postbiotic
- health index
- improving
- candidate substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000968 intestinal effect Effects 0.000 title claims description 152
- 238000000034 method Methods 0.000 title claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 159
- 230000036541 health Effects 0.000 claims description 102
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 96
- 239000000126 substance Substances 0.000 claims description 87
- 230000006872 improvement Effects 0.000 claims description 47
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 38
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 35
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 32
- 238000004364 calculation method Methods 0.000 claims description 28
- 235000019260 propionic acid Nutrition 0.000 claims description 19
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 19
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims 2
- 230000007423 decrease Effects 0.000 description 20
- 238000010586 diagram Methods 0.000 description 16
- 210000000936 intestine Anatomy 0.000 description 11
- 230000008859 change Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 208000037062 Polyps Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IAIWVQXQOWNYOU-BAQGIRSFSA-N [(z)-(5-nitrofuran-2-yl)methylideneamino]urea Chemical compound NC(=O)N\N=C/C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-BAQGIRSFSA-N 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
第1の実施例によると、ポストバイオティクス基盤健康指数算出部210は、対照群401の培養物に対するポストバイオティクス基盤健康指数を算出し、各腸内環境改善候補物質403を通じて培養された各培養物に対するポストバイオティクス基盤健康指数を算出しても良い。このとき、ポストバイオティクス基盤健康指数は、培養物の短鎖脂肪酸(SCFA、short-chain fatty acid)の割合に基づく指数であっても良い。ここで、短鎖脂肪酸は、炭素数が6以下である短い脂肪酸を意味し、腸内微生物から生成される代表的な代謝産物である。また、短鎖脂肪酸は、免疫力の増加、腸内リンパ球の安定、インシュリン信号低下、交感神経刺激など、体内に有用な機能を有している。係る短鎖脂肪酸は、代表的に酢酸(Acetate)、プロピオン酸(Propionate)、酪酸(Butyrate)があるが、これに限定されるものではない。ここで、ポストバイオティクス基盤健康指数は、プロピオン酸(Propionate)及び酪酸(Butyrate)に対する酢酸(Acetate)の割合に基づく指数であっても良い。
第2の実施例によると、ポストバイオティクス基盤健康指数算出部210は、試料に少なくとも1つの腸内環境改善候補物質を処理した少なくとも1つの培養物の酢酸及び酪酸のそれぞれの増減及び含量に基づき、ポストバイオティクス基盤健康指数を算出しても良い。
Claims (6)
- ソリューション提供サーバによって実行されるポストバイオティクス基盤健康指数に基づき腸内環境改善のためのカスタマイズソリューションを提供する方法において、
ユーザ端末から試料を採取するためのキット(Kit)の登録を受けるステップと、
前記試料に少なくとも1つの腸内環境改善候補物質を処理した少なくとも1つの培養物のポストバイオティクス基盤健康指数を算出するステップと、
前記少なくとも1つの培養物のポストバイオティクス基盤健康指数に基づき、前記少なくとも1つの腸内環境改善候補物質を含む少なくとも1つの腸内環境改善のための製品を推薦するステップとを含み、
前記ポストバイオティクス基盤健康指数は、前記培養物の短鎖脂肪酸を構成するプロピオン酸(Propionate)及び酪酸(Butyrate)に対する酢酸(Acetate)の割合に基づいて計算され、
前記ポストバイオティクス基盤健康指数を算出するステップは、
前記少なくとも1つの腸内環境改善候補物質を処理した試料の酢酸の含量と前記腸内環境改善候補物質を処理していない対照群の酢酸の含量との酢酸含量差に関する第1の差値、及び前記少なくとも1つの腸内環境改善候補物質を処理した試料の酪酸の含量と前記対照群の酪酸の含量との酪酸含量差、又は前記少なくとも1つの腸内環境改善候補物質を処理した試料のプロピオン酸の含量と前記対照群のプロピオン酸の含量とのプロピオン酸含量差に関する第2の差値を計算するステップと、
前記酢酸含量差をX軸、前記酪酸含量差又はプロピオン酸含量差をY軸とする座標平面において、前記第1の差値及び前記第2の差値に対応する座標点と前記X軸とがなす角度に基づいて前記少なくとも1つの腸内環境改善候補物質を選定するステップとを含む、腸内環境改善のためのカスタマイズソリューション提供方法。 - 前記ポストバイオティクス基盤健康指数を算出するステップは、前記試料に前記腸内環境改善候補物質を処理していない対照群のポストバイオティクス基盤健康指数と前記少なくとも1つの培養物のポストバイオティクス基盤健康指数との差が最も大きい培養物を選定するステップを含み、
前記少なくとも1つの腸内環境改善のための製品を推薦するステップは、前記差が最も大きい培養物の培養のために処理した腸内環境改善候補物質を含む前記腸内環境改善のための製品を推薦するステップを含む、請求項1に記載の腸内環境改善のためのカスタマイズソリューション提供方法。 - 前記腸内環境改善のための製品は、プロバイオティクス、プレバイオティクス、食品、健康機能性食品及び医薬品のうち少なくとも1つを含む、請求項1に記載の腸内環境改善のためのカスタマイズソリューション提供方法。
- ポストバイオティクス基盤健康指数に基づき腸内環境改善のためのカスタマイズソリューションを提供するサーバにおいて、
ユーザ端末から試料を採取するためのキット(Kit)の登録を受けるキット登録部と、
前記試料に少なくとも1つの腸内環境改善候補物質を処理した少なくとも1つの培養物のポストバイオティクス基盤健康指数を算出するポストバイオティクス基盤健康指数算出部と、
前記少なくとも1つの培養物のポストバイオティクス基盤健康指数に基づき、前記少なくとも1つの腸内環境改善候補物質を含む少なくとも1つの腸内環境改善のための製品を推薦する製品推薦部とを含み、
前記ポストバイオティクス基盤健康指数は、前記培養物の短鎖脂肪酸を構成するプロピオン酸(Propionate)及び酪酸(Butyrate)に対する酢酸(Acetate)の割合に基づいて計算され、
前記ポストバイオティクス基盤健康指数算出部は、
前記少なくとも1つの腸内環境改善候補物質を処理した試料の酢酸の含量と前記腸内環境改善候補物質を処理していない対照群の酢酸の含量との酢酸含量差に関する第1の差値、及び前記少なくとも1つの腸内環境改善候補物質を処理した試料の酪酸の含量と前記対照群の酪酸の含量との酪酸含量差、又は前記少なくとも1つの腸内環境改善候補物質を処理した試料のプロピオン酸の含量と前記対照群のプロピオン酸の含量とのプロピオン酸含量差に関する第2の差値を計算し、
前記酢酸含量差をX軸、前記酪酸含量差又はプロピオン酸含量差をY軸とする座標平面において、前記第1の差値及び前記第2の差値に対応する座標点と前記X軸とがなす角度に基づいて前記少なくとも1つの腸内環境改善候補物質を選定する、ソリューション提供サーバ。 - 前記ポストバイオティクス基盤健康指数算出部は、前記試料に前記腸内環境改善候補物質を処理していない対照群のポストバイオティクス基盤健康指数と前記少なくとも1つの培養物のポストバイオティクス基盤健康指数との差が最も大きい培養物を選定し、
前記製品推薦部は、前記差が最も大きい培養物の培養のために処理した腸内環境改善候補物質を含む前記腸内環境改善のための製品を推薦する、請求項4に記載のソリューション提供サーバ。 - 前記腸内環境改善のための製品は、プロバイオティクス、プレバイオティクス、食品、健康機能性食品及び医薬品のうち少なくとも1つを含む、請求項4に記載のソリューション提供サーバ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0009519 | 2020-01-23 | ||
KR1020200009519A KR102373889B1 (ko) | 2020-01-23 | 2020-01-23 | 장내 환경 개선을 위한 맞춤형 솔루션을 제공하는 방법 및 서버 |
PCT/KR2020/018343 WO2021149919A1 (ko) | 2020-01-23 | 2020-12-15 | 장내 환경 개선을 위한 맞춤형 솔루션을 제공하는 방법 및 서버 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023511393A JP2023511393A (ja) | 2023-03-17 |
JP7398571B2 true JP7398571B2 (ja) | 2023-12-14 |
Family
ID=76993055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022544435A Active JP7398571B2 (ja) | 2020-01-23 | 2020-12-15 | 腸内環境改善のためのカスタマイズソリューションを提供する方法及びサーバ |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230045372A1 (ja) |
JP (1) | JP7398571B2 (ja) |
KR (1) | KR102373889B1 (ja) |
CN (1) | CN115004318A (ja) |
AU (1) | AU2020424401A1 (ja) |
CA (1) | CA3165178A1 (ja) |
WO (1) | WO2021149919A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003504409A (ja) | 1999-07-20 | 2003-02-04 | ラボラトワレ スタンダ ソシエテ アノニム | 結腸においてプロピオン酸および/またはプロピオン酸塩を産生する目的でのプロピオン酸菌の使用 |
WO2014126043A1 (ja) | 2013-02-12 | 2014-08-21 | 公益財団法人がん研究会 | 食品成分及び食品組成物のスクリーニング方法 |
JP2016212584A (ja) | 2015-05-07 | 2016-12-15 | Kddi株式会社 | 検査結果管理装置、検査結果管理方法及び検査結果管理システム |
JP2019200687A (ja) | 2018-05-18 | 2019-11-21 | 株式会社サイキンソー | 腸内細菌の検査法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170085930A (ko) * | 2016-01-15 | 2017-07-25 | (주)바이오일레븐 | 장내 세균 분석을 통한 건강정보 제공방법 |
KR102486181B1 (ko) * | 2016-09-16 | 2023-01-06 | 소마젠 인크 | 패널 특성화를 위한 방법 및 시스템 |
KR101920219B1 (ko) * | 2017-03-08 | 2018-11-20 | 서울대학교산학협력단 | 비피더스균을 포함하는 비만 예방 또는 개선용 조성물 |
KR20190004586A (ko) | 2017-07-04 | 2019-01-14 | (주)바이오일레븐 | 장내미생물이식(fmt)을 위한 기증자 및 기증자 분변 선별방법 |
KR101936402B1 (ko) * | 2017-12-28 | 2019-01-08 | 가천대학교 산학협력단 | 장내 미생물 검사 기반 식단 제공 시스템 및 방법 |
WO2019168391A1 (ko) * | 2018-03-02 | 2019-09-06 | 한동대학교 산학협력단 | Pmas방법을 이용한 개인 맞춤형 프로바이오틱스, 식품, 건강기능성 식품 및 의약품 스크리닝 방법 |
-
2020
- 2020-01-23 KR KR1020200009519A patent/KR102373889B1/ko active IP Right Grant
- 2020-12-15 US US17/793,836 patent/US20230045372A1/en active Pending
- 2020-12-15 WO PCT/KR2020/018343 patent/WO2021149919A1/ko active Application Filing
- 2020-12-15 CN CN202080094341.3A patent/CN115004318A/zh active Pending
- 2020-12-15 AU AU2020424401A patent/AU2020424401A1/en active Pending
- 2020-12-15 JP JP2022544435A patent/JP7398571B2/ja active Active
- 2020-12-15 CA CA3165178A patent/CA3165178A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003504409A (ja) | 1999-07-20 | 2003-02-04 | ラボラトワレ スタンダ ソシエテ アノニム | 結腸においてプロピオン酸および/またはプロピオン酸塩を産生する目的でのプロピオン酸菌の使用 |
WO2014126043A1 (ja) | 2013-02-12 | 2014-08-21 | 公益財団法人がん研究会 | 食品成分及び食品組成物のスクリーニング方法 |
JP2016212584A (ja) | 2015-05-07 | 2016-12-15 | Kddi株式会社 | 検査結果管理装置、検査結果管理方法及び検査結果管理システム |
JP2019200687A (ja) | 2018-05-18 | 2019-11-21 | 株式会社サイキンソー | 腸内細菌の検査法 |
Also Published As
Publication number | Publication date |
---|---|
US20230045372A1 (en) | 2023-02-09 |
CA3165178A1 (en) | 2021-07-29 |
JP2023511393A (ja) | 2023-03-17 |
CN115004318A (zh) | 2022-09-02 |
KR102373889B1 (ko) | 2022-03-15 |
AU2020424401A1 (en) | 2022-08-04 |
KR20210095510A (ko) | 2021-08-02 |
WO2021149919A1 (ko) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vinderola et al. | The concept of postbiotics | |
Zhu et al. | Meat, dairy and plant proteins alter bacterial composition of rat gut bacteria | |
Rackaityte et al. | The human microbiome in the 21st century | |
Malacarne et al. | New insights into chemical and mineral composition of donkey milk throughout nine months of lactation | |
Sun et al. | Non-energy-restricted low-carbohydrate diet combined with exercise intervention improved cardiometabolic health in overweight Chinese females | |
Damianidi et al. | Protein intakes and their nutritional sources during the first 2 years of life: secondary data evaluation from the European Childhood Obesity Project | |
Kováčová et al. | Assessment of quality and safety of farm level produced cheeses from sheep and goat milk | |
Adewole et al. | Gut microbiota dynamics, growth performance, and gut morphology in broiler chickens fed diets varying in energy density with or without bacitracin methylene disalicylate (Bmd) | |
Iriondo-DeHond et al. | Nutritional quality, sensory analysis and shelf life stability of yogurts containing inulin-type fructans and winery byproducts for sustainable health | |
Harakeh et al. | Impact of smoking cessation, coffee and bread consumption on the intestinal microbial composition among Saudis: A cross-sectional study | |
JP2023093682A (ja) | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 | |
Barbaccia et al. | Monitoring commercial starter culture development in presence of red grape pomace powder to produce polyphenol-enriched fresh ovine cheeses at industrial scale level | |
Stinson et al. | Effect of cold storage on the viable and total bacterial populations in human milk | |
Cho et al. | Effect of searing process on quality characteristics and storage stability of sous-vide cooked pork patties | |
Ambrosio et al. | Effects of different levels of inclusion of apulo-calabrese pig meat on microbiological, physicochemical and rheological parameters of salami during ripening | |
Pires et al. | Evaluation of the characteristics of sheep’s and goat’s ice cream, produced with UF concentrated second cheese whey and different starter cultures | |
JP7398571B2 (ja) | 腸内環境改善のためのカスタマイズソリューションを提供する方法及びサーバ | |
Martín et al. | Evolution of volatile compounds during ripening and final sensory changes of traditional raw ewe’s milk cheese “Torta del Casar” maturated with selected protective lactic acid bacteria | |
Garofalo et al. | Development of “Quadrello di Ovino”, a novel fresh ewe’s cheese | |
Szopa et al. | Effect of Collagen Types, Bacterial Strains and Storage Duration on the Quality of Probiotic Fermented Sheep’s Milk | |
Czyżak-Runowska et al. | Lactose Content and Selected Quality Parameters of Sheep Milk Fermented Beverages during Storage | |
Yousaf et al. | The Effects of Cranberry Polyphenol Extract (CPE) Supplementation on Astringency and Flavor Perception as a Function of PROP Taster Status and Other Individual Factors | |
Gacek et al. | Satisfaction with life and nutritional behaviour, body composition, and functional fitness of women from the Kraków population participating in the “healthy active senior” programme | |
Tzora et al. | The “Crosstalk” between Microbiota and Metabolomic Profile of Kefalograviera Cheese after the Innovative Feeding Strategy of Dairy Sheep by Omega-3 Fatty Acids | |
Heller et al. | Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220721 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231121 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7398571 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |